Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00673179 · ClinicalTrials.gov registry record · NA
Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy
A NA study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT00673179: Clinical Trial NA study, sponsored by M.D. Anderson Cancer Center.
NCT00673179 is a NA study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00673179, a NA study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if giving certain combinations of chemotherapy drugs before and after surgery, mostly in the outpatient clinic instead of in the hospital, can result in fewer hospital stays during treatment for osteosarcoma. The drugs and schedules will vary depending on the status of the cancer and its level of risk for spreading, but they will include combinations of doxorubicin (non-liposomal), cisplatin, methotrexate, and ifosfamide, as described below.
Interventions
- DRUG Cisplatin
- DRUG Doxorubicin
- DRUG Leucovorin
- DRUG Methotrexate
- DRUG Dexrazoxane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00673179
The ClinicalTrials.gov registry entry for NCT00673179 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT00673179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00673179 about?
NCT00673179 is a clinical study titled "Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy". The goal of this clinical research study is to learn if giving certain combinations of chemotherapy drugs before and after surgery, mostly in the outpatient clinic instead of in the hospital, can result in fewer hospital stays during treatment for osteosarcoma. The drugs and schedules will vary depe...
What is the current status of trial NCT00673179?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2008-05. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00673179?
The interventions under investigation include: Cisplatin (DRUG), Doxorubicin (DRUG), Leucovorin (DRUG), Methotrexate (DRUG), Dexrazoxane (DRUG).
Who is sponsoring clinical trial NCT00673179?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.